免疫介导的血小板折射性:机制,诊断和治疗突破
Lei Ma1, Lina Wu1, Jinhui Xie1
1Tianjin Blood Center, Tianjin, China.
Transfusion medicine (Oxford, England)
|March 7, 2026
概括
免疫介导的血小板输血折射性 (PTR) 通常是由对抗人类白细胞抗原 (HLA) 或人类血小板抗原 (HPA) 的抗体引起的. 新型疗法有前途,但需要进一步的临床验证才能改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 输血医学 输血医学
背景情况:
- 血小板是关键的免疫媒介,而免疫媒介的血小板输血折射性 (PTR) 提出了临床挑战.
- 对人类白细胞抗原 (HLA) 和人类血小板抗原 (HPA) 的合免疫是免疫媒介PTR的主要驱动因素.
- 目前用于免疫媒介PTR的治疗方法往往不理想,因此需要研究先进的诊断和新型治疗方法.
研究的目的:
- 审查当前关于抗体致病的知识,检测方法和免疫介导PTR的新疗法.
- 为临床决策提供信息,并指导该领域的未来研究.
- 综合有关HLA/HPA抗体检测和PTR治疗创新的证据.
主要方法:
- 对同行评审文章进行了全面的文献综述.
- 专注于免疫介导的PTR,非免疫化机制,诊断技术和治疗创新.
- 分析了关键研究和新兴数据,以确定知识差距和评估当前证据.
主要成果:
- 免疫介导的PTR由针对HLA类I和/或HPA的类抗体产生的,导致血小板清除加速.
- 先进的检测方法,如多重珠数组,可以提高不兼容的捐赠者的识别.
- 包括血小板基因组编辑和免疫调节在内的新策略正在调查中,但缺乏临床验证.
结论:
- 同免疫显著促进免疫介导的PTR,强调了对准确的抗体检测和抗原匹配的需要.
- 对于一些患者来说,PTR的现有疗法仍然不足于最佳水平.
- 新兴技术具有治疗潜力,但需要严格的临床评估来改善PTR管理.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:27Peripheral Artery Disease III: Interprofessional Care
469
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
469
01:22Formation of the Platelet Plug
10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K